PomDoctor Ltd (POM) Stock Analysis
Verdict: AVOID
Extreme insolvency risk and $149.5M annual cash burn make POM non-investable despite its transition from ADRs to direct listing.
Investment score: 14/100
Analysis as of
Is PomDoctor Ltd stock worth reviewing? The TradeMates thesis
TradeMates sees PomDoctor Ltd as a high-risk micro-cap distressed company facing imminent liquidity pressures. Operational loss margins (-83.7% TTM net margin) and $454.9M in total debt make long-term equity value highly unlikely to survive without catastrophic dilution or restructuring.
7-factor investment score
- Valuation: 25/100 (weight 20%)
- Financial Health: 5/100 (weight 15%)
- Technical Momentum: 15/100 (weight 15%)
- Earnings Quality: 10/100 (weight 15%)
- Insider Sentiment: 20/100 (weight 10%)
- Analyst Consensus: 20/100 (weight 10%)
- Risk-Adjusted Return: 5/100 (weight 15%)
PomDoctor Ltd opportunities and risks
What speaks for POM
- ADR program termination streamlines capital structure
What speaks against POM
- Severe cash runway depletion and imminent capital shortage
Peers and competitors
- 6833.HK
- 1110.HK
- 2211.HK
- KPEA
- 601607.SS
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| POM | n/a | 0.2x | n/a | 11.7% | -83.7% | -192.4% |
| KPEA | n/a | 21.6x | n/a | 20.2% | -225.8% | 0.2% |
| Peer median | n/a | 21.6x | n/a | 20.2% | -225.8% | 0.2% |
Frequently asked questions about PomDoctor Ltd (POM)
Is POM stock a good investment?
The TradeMates model rates PomDoctor Ltd as AVOID with an investment score of 14/100. TradeMates sees PomDoctor Ltd as a high-risk micro-cap distressed company facing imminent liquidity pressures. Operational loss margins (-83.7% TTM net margin) and $454.9M in total debt make long-term equity value highly unlikely to survive without catastrophic dilution or restructuring. This is algorithmic model output, not personal investment advice.
Is POM stock a buy?
The TradeMates model verdict for POM is AVOID with an investment score of 14/100. Treat this as a model signal to review, not a personal buy recommendation.